CardiaTec aims to revolutionize cardiovascular disease treatment by utilizing advanced AI techniques to accelerate drug discovery, addressing one of the leading global health threats.
'He (Han) is an academic who sits on the border with industry, so he understands that translational perspective,' Peralta told TechCrunch in an interview.
The average expense of progressing a drug candidate from discovery through launch is around $2.2 billion, and that cost is driven primarily by lengthy trial durations.
CVDs are the preeminent cause of death globally, resulting in 17.9 million deaths each year, according to The World Health Organization (WHO).
Collection
[
|
...
]